⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Pathologic Changes in ELAVL3 Expression and Splicing Occur in TDP43 and Non-TDP43 Proteinopathies (P4-9.007)

Isabel Costantino Alex Meng John Ravits

View at Publisher

Ask AI

Bookmark

Share

Abstract

To describe the neuropathologic and splicing changes in the RNA binding protein (RBP) ELAVL3 in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Costantino et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db6435876781df https://doi.org/10.1212/wnl.0000000000208273

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Splicing the narrative: alternative TARDBP splicing and its relation to neurodegeneration in ALS and FTDReview · 2026 · 1 citations
2TDP-43-mediated alternative polyadenylation is associated with a reduction in VPS35 and VPS29 expression in frontotemporal dementiaOriginal Research · 2026 · 4 citations
3Alternative Splicing Alterations in Patients With Amyotrophic Lateral Sclerosis: Link to the Disruption of TAR DNA‐Binding Protein 43 kDa FunctionsOriginal Research · 2025 · 2 citations
4TDP-43 loss of function drives aberrant splicing in Parkinson's disease2025 · 1 citations
5Understanding age-related pathologic changes in TDP-43 functions and the consequence on RNA splicing and signalling in health and disease2024 · 15 citations

More related papers

ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-432013
TDP-43 pathology triggers SRRM4-dependent cryptic splicing of G3BP1 in ALS/FTD2025
Cryptic Splicing in ALS: From Driving Disease Progression to Unlocking Novel Therapeutics2026

More from Neurology

Blood-Based Biomarkers as Predictors of All-Cause DementiaFri,
Antidopaminergic Medications and Clinical Outcomes in Huntington DiseaseThu,